CoChat

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

A phase 1b study of transforming growth factor‐beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma

Open access

Abstract

Background Galunisertib inhibits type I transforming growth factor-beta receptor serine/threonine kinase. The primary objective of this study was to evaluate the safety and tolerability of galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. Patients and methods This open-label, dose-escalation, multicenter, nonrandomized phase 1b study consisted of two dose levels of galunisertib, 160 or 300 mg/day, in combination with sorafenib 800 mg/day. Galunisertib 80 mg or 150 mg was administered orally twice daily for 14 days followed by 14 days of rest plus sorafenib 400 mg administered orally twice daily for 28 days. The dose-limiting toxicity evaluation was 28 days after the first dose. Safety measures, pharmacokinetics, and antitumor activity were assessed. Results Fourteen patients, 7 at each galunisertib dose, were enrolled and treated. Three dose-limiting toxicities were reported for 2 patients. The most common treatment-emergent adverse events (TEAEs) were hypophosphatemia (14 patients [100%]), palmar-plantar erythrodysesthesia syndrome (12 patients [85.7%]), and decreased platelet count (10 patients [71.4%]). The most common grade ≥ 3 TEAEs were hypophosphatemia (10 patients [71.4%]) and palmar-plantar erythrodysesthesia syndrome (7 patients [50.0%]). No grade 5 TEAEs were reported. The pharmacokinetic profile of galunisertib in combination with sorafenib was similar to that previously reported for galunisertib. Eleven patients had a best overall response of stable disease, and 1 patient achieved a partial response by hepatocellular carcinoma-specific modified RECIST. Conclusions These data are consistent with the known safety profile for galunisertib and sorafenib and confirm tolerability of the recommended dose of galunisertib (150 mg twice daily for 14 days) in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-018-0636-3

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Arithmetic mean (plus standard deviation) plasma galunisertib concentration-time profiles on cycle 1 days 1 and 14 following administration of galunisertib 160 mg/day or 300 mg/day. Linear plot (a); semi-logarithmic plot (b)
Fig. 1 Arithmetic mean (plus standard deviation) plasma galunisertib concentration-time profiles on cycle 1 days 1 and 14 following administration of galunisertib 160 mg/day or 300 mg/day. Linear plot (a); semi-logarithmic plot (b)CC BY · PubMed Central
Fig. 2 Best percentage change in tumor size with galunisertib 160 mg/day plus sorafenib (a and c) and galunisertib 300 mg/day plus sorafenib (b and d). Data are derived from RECIST assessment (a and b) and mRECIST assessment (c and d). Numbers below each graph indicate the number of cycles of study treatment received by each patient. Abbreviations: mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease
Fig. 2 Best percentage change in tumor size with galunisertib 160 mg/day plus sorafenib (a and c) and galunisertib 300 mg/day plus sorafenib (b and d). Data are derived from RECIST assessment (a and b) and mRECIST assessment (c and d). Numbers below each graph indicate the number of cycles of study treatment received by each patient. Abbreviations: mRECIST = modified Response Evaluation Criteria in Solid Tumors; NE = not evaluable; PD = progressive disease; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable diseaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 46

Metadata

Authors
Ikeda, M., Morimoto, M., Tajimi, M., Inoue, K., Benhadji, K. A., Lahn, M. M. F., & Sakai, D.
Affiliations
  • National Cancer Center Hospital East (JP)
  • Kanagawa Cancer Center (JP)
  • Eli Lilly (Japan) (JP)
  • Eli Lilly (United States) (US)
  • Osaka University Hospital (JP)
Corresponding author
Ikeda, Masafumi
Venue
Investigational New Drugs
Published
2018-07-11
Volume
37
Issue
1
Pages
118-126
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2856466152
Cited by
46
References
23
Citations by year
2026: 2 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 8 · 2020: 8 · 2019: 3
FWCI
2.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Investigational New Drugs (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
galunisertib, sorafenib, hepatocellular carcinoma, unresectable liver cancer, combination therapy, dose-limiting toxicity, hypophosphatemia, palmar-plantar erythrodysesthesia syndrome, pharmacokinetics, anticancer activity, Japanese patients
MeSH terms
Sorafenib, Receptor, Transforming Growth Factor-beta Type I, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Prognosis, Pyrazoles, Quinolines, Tissue Distribution, Maximum Tolerated Dose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 1b study of transforming growth factor‐beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. https://app.cochat.ai/papers/10.1007/s10637-018-0636-3
The paper
Ikeda, M., Morimoto, M., Tajimi, M., Inoue, K., Benhadji, K. A., Lahn, M. M. F., & Sakai, D. (2019). A phase 1b study of transforming growth factor‐beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. Investigational New Drugs. https://doi.org/10.1007/s10637-018-0636-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.